Delivery Order SPE2DB24D2100-SPE2DB26FBAMM
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for EUFLEXXA 1% 20 mg/2 mL syringes with a ceiling value of $6,754.59 on August 14, 2025. This is a firm fixed price delivery order with an ultimate completion date of August 15, 2025, and no set-aside designation was used. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $5,342.85 to AmerisourceBergen Drug Corp for EUFLEXXA 1% 20 mg/2 ml syringes on September 11, 2025, with completion scheduled for September 12, 2025. EUFLEXXA is a hyaluronic acid-based injectable treatment commonly used for knee osteoarthritis pain management. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $16,891.11 to AmerisourceBergen Drug Corp for EUFLEXXA 1% 20 mg/2 mL syringes (2 mL quantity) on October 31, 2025, with completion scheduled for November 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. EUFLEXXA is a hyaluronic acid injection used for osteoarthritis treatment,...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of EUFLEXXA 1% 20 mg/2 ml syringes in 2 ml quantities. This is a firm fixed price delivery order with a ceiling value of $2,575.50 and an ultimate completion date of July 30, 2025. The award was made on a competitive, non-set-aside basis to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. EUFLEXXA is a viscosupplementation...
- The Defense Logistics Agency awarded a $4,680.85 firm fixed-price delivery order to AmerisourceBergen Drug Corp for EUFLEXXA 1% 20 mg/2 mL syringes (2 mL quantity) on September 12, 2025, with an ultimate completion date of September 15, 2025. This non-set-aside contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $10,745.36 to AmerisourceBergen Drug Corp for the supply of EUFLEXXA 1% 20 mg/2 mL syringes on September 17, 2025, with an ultimate completion date of September 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. EUFLEXXA is a hyaluronic acid-based injectable product used for osteoarthritis treatment, representing...
- The Defense Logistics Agency awarded a $23.6K delivery order to AmerisourceBergen Drug Corp for EUFLEXXA 1% 20 MG/2 ML syringes on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitive, firm fixed-price delivery order represents a continuation of AmerisourceBergen's substantial pharmaceutical supply relationship with DLA, leveraging the company's position as a critical distributor of medical products for federal healthcare systems. The award carries no...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the procurement of EUFLEXXA 20 MG/2 ML SYRINGE 2ML. The contract, valued at $3,003.66, has a completion date of February 27, 2024. Amerisourcebergen Drug Corp, a for-profit organization located in Conshohocken, Pennsylvania, serves as the prime contractor and is responsible for delivering the pharmaceutical product to...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of EUFLEXXA 1% 20 mg/2 ml syringes with a ceiling value of $3,670.26. EUFLEXXA is a hyaluronic acid-based injectable treatment used for knee osteoarthritis pain management. This competitive delivery order, executed under firm fixed pricing, represents a continuation of the federal medical procurement relationship between the prime contractor and the...
- The Defense Logistics Agency awarded a $2,660.25 delivery order to AmerisourceBergen Drug Corp on July 10, 2025, for EUFLEXXA 1% 20 mg/2 ml syringes. This firm fixed-price delivery order, which is expected to be completed by July 11, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made on a competitive basis with no set-aside designation and represents a child delivery order under a larger contract vehicle with DLA....
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB26FBAMMDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,891.21 to AmerisourceBergen Drug Corp for EUFLEXXA 1% 20 mg/2 ml syringes (2 ml units) with an ultimate completion date of October 29, 2025. This is a firm fixed-price contract with no set-aside designation, competitively awarded through an open procurement process. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The parent IDC vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This delivery order for EUFLEXXA, a hyaluronic acid-based joint injection used in orthopedic care, exemplifies the company's role in supporting the Defense Health Agency and other federal healthcare systems through flexible contract mechanisms designed to meet evolving medical supply needs across the military healthcare infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.9k | 10/28/25 |